BR112021022843A2 - Composto para tratamento de gota ou hiperuricemia - Google Patents

Composto para tratamento de gota ou hiperuricemia

Info

Publication number
BR112021022843A2
BR112021022843A2 BR112021022843A BR112021022843A BR112021022843A2 BR 112021022843 A2 BR112021022843 A2 BR 112021022843A2 BR 112021022843 A BR112021022843 A BR 112021022843A BR 112021022843 A BR112021022843 A BR 112021022843A BR 112021022843 A2 BR112021022843 A2 BR 112021022843A2
Authority
BR
Brazil
Prior art keywords
hyperuricemia
compound
gout
treatment
methanone
Prior art date
Application number
BR112021022843A
Other languages
English (en)
Portuguese (pt)
Inventor
Litain Yeh
Rongzi Yan
Shunqi Yan
Zancong Shen
Original Assignee
Arthrosi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthrosi Therapeutics Inc filed Critical Arthrosi Therapeutics Inc
Publication of BR112021022843A2 publication Critical patent/BR112021022843A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
BR112021022843A 2019-05-14 2020-05-13 Composto para tratamento de gota ou hiperuricemia BR112021022843A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847519P 2019-05-14 2019-05-14
PCT/US2020/032725 WO2020232156A1 (en) 2019-05-14 2020-05-13 Compound for treating gout or hyperuricemia

Publications (1)

Publication Number Publication Date
BR112021022843A2 true BR112021022843A2 (pt) 2022-03-03

Family

ID=73288915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022843A BR112021022843A2 (pt) 2019-05-14 2020-05-13 Composto para tratamento de gota ou hiperuricemia

Country Status (14)

Country Link
US (1) US20220242841A1 (https=)
EP (1) EP3968989A4 (https=)
JP (1) JP7656548B2 (https=)
KR (1) KR20220016105A (https=)
CN (1) CN113874014A (https=)
AU (2) AU2020274165A1 (https=)
BR (1) BR112021022843A2 (https=)
CA (1) CA3140412A1 (https=)
IL (1) IL288034B1 (https=)
MA (1) MA55973A (https=)
MX (1) MX2021013980A (https=)
SG (1) SG11202112562XA (https=)
TW (1) TW202108561A (https=)
WO (1) WO2020232156A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105743RA (en) 2018-12-06 2021-06-29 Arthrosi Therapeutics Inc Methods for treating or preventing gout or hyperuricemia
KR102946486B1 (ko) 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
KR20230024354A (ko) * 2020-06-10 2023-02-20 아쓰로시 테라퓨틱스, 인크. 만성 신장 질환을 치료 또는 예방하는 방법
WO2023058975A1 (ko) * 2021-10-07 2023-04-13 (주)이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물
TW202330485A (zh) * 2021-12-02 2023-08-01 美商安索治療公司 用於治療或預防痛風或高尿酸血症之化合物的結晶形式
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia
US20250242050A1 (en) 2024-01-31 2025-07-31 The Industry & Academic Cooperation In Chungnam National University (Iac) Composition for treating gout containing cyclodextrin-conjugated polymer nano-drug and method for treating gout

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
EP3484862B1 (en) * 2016-07-18 2021-09-01 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
US20210130312A1 (en) * 2018-04-03 2021-05-06 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
KR102946486B1 (ko) * 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형

Also Published As

Publication number Publication date
JP2022533958A (ja) 2022-07-27
MA55973A (fr) 2022-03-23
JP7656548B2 (ja) 2025-04-03
CN113874014A (zh) 2021-12-31
WO2020232156A1 (en) 2020-11-19
KR20220016105A (ko) 2022-02-08
EP3968989A4 (en) 2022-12-28
IL288034B1 (en) 2026-04-01
SG11202112562XA (en) 2021-12-30
IL288034A (en) 2022-01-01
EP3968989A1 (en) 2022-03-23
MX2021013980A (es) 2022-04-01
TW202108561A (zh) 2021-03-01
AU2026202224A1 (en) 2026-04-09
AU2020274165A1 (en) 2022-01-06
CA3140412A1 (en) 2020-11-19
US20220242841A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
BR112021022843A2 (pt) Composto para tratamento de gota ou hiperuricemia
MX2025002170A (es) Inhibidores de kras g12c
PH12020551464A1 (en) Cd73 inhibitors
BR112021026445A2 (pt) Composições e métodos para tratar distúrbios de cns
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
JOP20190076B1 (ar) مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
EA202191545A1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии
PH12021550713A1 (en) Medicament for the treatment of chronic cough
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EA202191543A1 (ru) Способы лечения или профилактики подагры или гиперурикемии
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
MX2022007626A (es) Combinaciones.
EA202090180A1 (ru) Композиции nk1-антагониста и способы лечения депрессии
JOP20220007A1 (ar) طرق للعلاج أو الوقاية من ضمور العضلات النخاعي
AR119159A1 (es) Tratamientos de angioedema
PH12020551772A1 (en) Oxo-substituted compound
EA202090194A1 (ru) Композиции статинов и способы их применения при лечении синуклеинопатий
EA202092540A1 (ru) Комбинации для лечения рака
MX2024010644A (es) Uso de iptacopan para el tratamiento de la nefritis lupica.
EA202193276A1 (ru) Способы лечения холангиокарциномы
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2021009717A (es) Sulfonamidas biciclicas.
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
BR112022022628A2 (pt) Inibidor de dhodh para o tratamento de covid-19